Formycon AG (FSB: FYB, Prime Standard) announced today that it will release its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will host a conference call and webcast at 3:00 PM CEST to discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year. The call will be conducted in English, with registration available at https://webcast.meetyoo.de/reg/lNibT8TVWubG. Participants will receive a confirmation email with dial-in details. The presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy, and a recording will be available on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
In the second quarter of 2026, Formycon's management will attend several international investor conferences. On May 11-12, CFO Enno Spillner will represent the company at the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, the company will publish its first quarter 2026 results, followed by a conference call with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. From June 2-4, CFO Spillner will participate in the Jefferies Global Healthcare Conference in New York City. On June 8, the management team will host a webcast for the mwb research Roundtable. The Annual General Meeting is scheduled for June 10 in Munich, and on June 18, CFO Spillner will attend the UBS Life Sciences Conference in London. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon is a leading independent developer of biosimilars, with a focus on ophthalmology, immunology, and immuno-oncology. The company has two marketed biosimilars—FYB201/ranibizumab and FYB202/ustekinumab—and FYB203/aflibercept has received approvals from the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208/dupilumab, are in development. The biosimilar market is expected to grow significantly, with global sales projected to rise from around $21 billion to over $74 billion by 2030, as many blockbuster biologics lose patent protection.
